Effects of cannabigerol and THC on pain and appetite
Analgesic and Appetite-stimulating Effects of Cannabigerol Administered Alone and in Combination With Delta-9-tetrahydrocannabinol
This study is testing whether cannabigerol (CBG) alone or with THC can help reduce pain and increase appetite in healthy people who occasionally use cannabis.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 21 Years to 55 Years |
| Sex | All |
| Sponsor | University of California, Los Angeles Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT04859296 on ClinicalTrials.gov |
What this trial studies
This study evaluates the analgesic and appetite-stimulating effects of cannabigerol (CBG) alone and in combination with THC in healthy, occasional cannabis smokers. It employs a double-blind, placebo-controlled, within-subject design to determine the dose-dependent effects of these compounds. Participants will receive various doses of CBG and THC to assess their impact on pain relief and appetite enhancement. The study aims to provide insights into the therapeutic potential of these cannabinoids.
Who should consider this trial
Good fit: Ideal candidates are healthy males or non-pregnant, non-lactating females aged 21-55 who are occasional cannabis users.
Not a fit: Patients with moderate-severe cannabis use disorder or other significant substance use disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer new treatment options for managing pain and appetite loss using cannabinoids.
How similar studies have performed: Other studies have shown promising results with cannabinoids for pain and appetite, but this specific combination approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or non-pregnant and non-lactating females aged 21-55 years * • Report occasional use of cannabis (cannabis use between ≥ biweekly and ≤ 3 days per week) over the month prior to screening * Not currently seeking treatment for their cannabis use * Have a Body Mass Index from 18.5 - 34kg/m2. * Able to perform all study procedures * Must be using a contraceptive (hormonal or barrier methods) * Females must not be lactating Exclusion Criteria: * Meeting DSM-V criteria for moderate-severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, or mild CUD * Any other Axis I disorder * • Current use of any medications within 14 days or 5 half-lives of administration (whichever is longer) except for hormonal contraceptives in females. If a medication is taken once a participant is enrolled, sessions will be suspended for 14 days or 5 half-lives after administration (whichever is longer) * If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures. * Current pain * Pregnancy is exclusionary due to the possible effects of the study medication on fetal development. * History of an allergic reaction or adverse reaction to cannabis is exclusionary. * History of respiratory illness or current respiratory illness * Currently enrolled in another research protocol * Not using a contraceptive method (hormonal or barrier methods) * Insensitivity to the cold water stimulus of the Cold Pressor Test * Any disorders that might make cannabis administration hazardous are exclusionary, as determined by the evaluating physician
Where this trial is running
Los Angeles, California
- University of California, Los Angeles — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Ziva D Cooper, PhD — University of California, Los Angeles
- Study coordinator: Ziva D Cooper, PhD
- Email: zcooper@mednet.ucla.edu
- Phone: 310-206-9942
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.